Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
Top Cited Papers
- 1 September 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (25), 6043-6053
- https://doi.org/10.1200/jco.2005.06.205
Abstract
Purpose Previously, we reported our experience treating 14 patients with metastatic melanoma using a fully human antibody to cytotoxic T-lymphocyte antigen-4 (anti–CTLA-4) in conjunction with pepti...Keywords
This publication has 42 references indexed in Scilit:
- Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV MelanomaJournal of Clinical Oncology, 2005
- Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic MelanomaJournal of Immunotherapy, 2004
- Adoptive-cell-transfer therapy for the treatment of patients with cancerNature Reviews Cancer, 2003
- T-cell regulation by CD28 and CTLA-4Nature Reviews Immunology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptorsImmunity, 1994
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994
- CTLA-4 is a second receptor for the B cell activation antigen B7.The Journal of Experimental Medicine, 1991